Citigroup’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.33M | Buy |
82,593
+70,587
| +588% | +$5.15M | ﹤0.01% | 1836 |
|
|
2026
Q1 | $606K | Sell |
12,006
-88,052
| -88% | -$3.32M | ﹤0.01% | 3438 |
|
|
2025
Q4 | $3.28M | Buy |
100,058
+67,162
| +204% | +$1.75M | ﹤0.01% | 2318 |
|
|
2025
Q3 | $551K | Buy |
32,896
+3,635
| +12% | +$59.3K | ﹤0.01% | 3525 |
|
|
2025
Q2 | $438K | Sell |
29,261
-54,203
| -65% | -$802K | ﹤0.01% | 3709 |
|
|
2025
Q1 | $1.35M | Buy |
83,464
+9,712
| +13% | +$202K | ﹤0.01% | 3038 |
|
|
2024
Q4 | $1.72M | Buy |
73,752
+48,561
| +193% | +$1.42M | ﹤0.01% | 2938 |
|
|
2024
Q3 | $741K | Buy |
25,191
+5,871
| +30% | +$163K | ﹤0.01% | 3482 |
|
|
2024
Q2 | $454K | Sell |
19,320
-12,437
| -39% | -$420K | ﹤0.01% | 3459 |
|
|
2024
Q1 | $1.2M | Buy |
31,757
+21,460
| +208% | +$622K | ﹤0.01% | 2879 |
|
|
2023
Q4 | $222K | Buy |
+10,297
| New | +$142K | ﹤0.01% | 3864 |
|
|
2022
Q4 | – | Sell |
-25
| Closed | – | – | 5950 |
|
|
2022
Q3 | $0 | Sell |
25
-182
| -88% | -$2.25K | ﹤0.01% | 6305 |
|
|
2022
Q2 | $3K | Buy |
207
+34
| +20% | +$1.19K | ﹤0.01% | 5800 |
|
|
2022
Q1 | $10K | Sell |
173
-303
| -64% | -$25.4K | ﹤0.01% | 5549 |
|
|
2021
Q4 | $56K | Buy |
476
+191
| +67% | +$30.1K | ﹤0.01% | 5005 |
|
|
2021
Q3 | $57K | Buy |
285
+86
| +43% | +$15K | ﹤0.01% | 4672 |
|
|
2021
Q2 | $35K | Buy |
199
+35
| +21% | +$6.36K | ﹤0.01% | 4990 |
|
|
2021
Q1 | $33K | Sell |
164
-239
| -59% | -$45.9K | ﹤0.01% | 4950 |
|
|
2020
Q4 | $79K | Buy |
403
+209
| +108% | +$43.3K | ﹤0.01% | 5728 |
|
|
2020
Q3 | $34K | Sell |
194
-153
| -44% | -$28.3K | ﹤0.01% | 5855 |
|
|
2020
Q2 | $80K | Sell |
347
-27
| -7% | -$5.14K | ﹤0.01% | 5761 |
|
|
2020
Q1 | $44K | Buy |
374
+70
| +23% | +$11.9K | ﹤0.01% | 6087 |
|
|
2019
Q4 | $58K | Buy |
304
+199
| +190% | +$39.1K | ﹤0.01% | 6194 |
|
|
2019
Q3 | $20K | Sell |
105
-193
| -65% | -$37.6K | ﹤0.01% | 6741 |
|
|
2019
Q2 | $51K | Buy |
298
+70
| +31% | +$12.1K | ﹤0.01% | 6461 |
|
|
2019
Q1 | $46K | Buy |
228
+60
| +36% | +$12.5K | ﹤0.01% | 6411 |
|
|
2018
Q4 | $32K | Sell |
168
-11
| -6% | -$2.33K | ﹤0.01% | 6582 |
|
|
2018
Q3 | $43K | Buy |
179
+85
| +90% | +$19.9K | ﹤0.01% | 6646 |
|
|
2018
Q2 | $25K | Buy |
+94
| New | +$23.1K | ﹤0.01% | 6810 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
Citigroup's SYRE Position: Q2 2026 in Review
Citigroup increased its Spyre Therapeutics (SYRE) stake by 588% in Q2 2026, buying an estimated $5.15M and bringing the position to 82,593 shares worth $7.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1836.
Citigroup first reported a position in SYRE in Q2 2018 and has held it in 29 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- Citigroup held 82,593 shares of Spyre Therapeutics worth $7.33M as of Q2 2026.
- Citigroup bought 70,587 Spyre Therapeutics shares in Q2 2026, an estimated $5.15M.
- Spyre Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1836 holding.
- Citigroup first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 29 quarters since.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.